Enhancing Gene Therapy through Targeted Delivery of CRIPSR/Cas9 in a Novel, Inexpensive Lipid Nanoparticle
CSEF · 2018 Biochemistry/ Molecular Biology Second Award
Overview
Objectives/Goals CRISPR/Cas9 has an enormous potential to treat chronic and genetic diseases through its versatility and efficiency in editing DNA. However, this technology has yet to be implemented because of the body's vigorous immune defenses against Cas9. Thus, the goal of the project is to develop a novel lipid nanoparticle that allows safe, targeted, and inexpensive delivery of Cas9. Methods/Materials Lipids nanoparticles were designed with a novel combination of lipids to allow immune evasion, dissociation within cells, and nontoxic metabolic degradation. Furthermore, a simple, inexpensive synthesis procedure was developed by optimizing thermodynamic favorability of the nanoparticle state. Polar headgroups of amphiphilic lipids adsorb to the polar Cas9 protein in a nonpolar environment, forming an inverse micelle. Upon dilution into an aqueous environment, nonpolar sites on inverse micelles attach to nonpolar sites on lipid tails to form the final nanoparticle with polar headgroups facing outwards. Fluorescent targeting antibodies were conjugated to the nanoparticle surface in a convenient nucleophilic substitution reaction. Encapsulation efficiency was tested by measuring Cas9 concentration before and after the synthesis procedure. Antibody conjugation efficiency was tested by measuring fluorescence before and after an antibody wash. Transfection efficiency was tested by adding the nanoparticles to cell lines and quantifying DNA editing after 48 hours. Results The nanoparticle shows an excellent ability to encapsulate Cas9, with an encapsulation efficiency of 55.6%. Further, antibody conjugation efficiency was measured at 79.9%. Editing efficiency was measured at 3.9%, more than 100 times higher than the editing efficiency of unencapsulated Cas9, and around 5 times higher than commercial transfection methods. Conclusions/Discussion The proposed nanoparticle design exhibits nontoxic transfection and immune evasion. The novel synthesis procedure eliminates the need for expensive machinery, allowing a projected cost of only $30 per treatment. The nanoparticle shows a robust ability to transfect and edit DNA within cells, paving the way for effective gene therapy towards diseases from diabetes to cystic fibrosis.
Summary statement
I designed and tested a lipid nanoparticle to cheaply and efficiently deliver CRISPR/Cas9 enzyme.
Help received
Eric Espinosa taught me how to maintain cell cultures. Eric Harness reviewed the project for safety hazards. All other aspects including conception of ideas and procedure, execution of experiments, and analysis of results were performed independently by me.
Awards (1)
Competition history
- CSEF 2018
Resources
Related projects
CSEF · 2016
A Permutable Nanotherapeutic Using Engineered CRISPR/Cas9: A Personalized Treatment for Cancer Heterogeneity and Viruses
CSEF · 2018
Augmenting Expression of Gene Editing CRISPR-SaCas9 through Codon Optimization to Boost in vivo Therapeutic Application
ISEF · 2025
Designing Ligand Functionalized Synthetic Exosomes for Targeted CRISPR-Cas9 Delivery: A Multistep Computational Approach to Cancer Treatment
ISEF · 2024
NanoFusion: Revolutionizing CRISPR/Cas9 Delivery to MCF-7 Adenocarcinoma via Exosome-Liposome Synergy
ISEF · 2017
Efficient Genome Editing of Mammalian Cells via Novel sgRNA Architectures and Cas9 Endonuclease
ISEF · 2018
Assessing the Impacts of CRISPR Editing on Protein Expression; Utilizing dCas9 as a Potential Roadblock to DNA Transcription
CYSF · 2025
Editing the Human Genome: Cell-Penetrating Peptide Based Delivery of CRISPR-Cas9 Components
ISEF · 2016
CRISPR/Cas9 Based Mechanisms for Controlled Gene Delivery with Applications for Alzheimer's and Pain Management for Veterans
Closest projects by meaning, across every fair and year in the corpus.
Browse more like this
Source: California Science & Engineering Fair public projects